| Name | AZD7545 |
| Description | AZD7545 is a potent PDHK inhibitor. |
| Kinase Assay | Cellular Kinase Assays: NIH3T3 cells prepared by transfection of human KDR. The cells are cultured in a collagen type I coated 96-well plate in an amount of 1.5 × 104 per well. The medium is then replaced by a DMEM medium containing 0.1% FCS. Ki8751 diluted in DMSO is added to each well and cultured. rhVEGF is added to a final concentration of 100 ng/mL, and the stimulation of cells is carried out at 37 °C. The cells are washed with PBS (pH 7.4), 50 μL of a solubilization buffer (20 mM HEPES (pH 7.4), 150 mM NaCl, 0.2% Triton X-100, 10% glycerol, 5 mM Na3VO4, 5 mM disodium ethylenediamine tetraacetate, and 2 mM Na4P2O7) is then added and a cell extract is prepared. Separately, PBS (50 μL, pH 7.4) containing 5 μg/mL of antiphosphotyrosine antibody (PY20) is added to a microplate for ELISA. After washing of the plate, 300 μL of a blocking solution is added. The cell extract is transferred to the plate. An anti-VEGFR2 antibody and a peroxidase-labeled anti-rabbit Ig antibody are added. Next, a chromophoric substrate for peroxidase is added, and the absorbance at 450 nm is measured with microplate reader. The VEGFR2 phosphorylation activity for each well is determined by presuming the absorbance with the addition of VEGF and without the addition of the test sample to be 100% VEGFR2 phosphorylation activity and VEGF to be 0% VEGFR2 phosphorylation activity. The concentration of the inhibition (%) of VEGFR2 Phosphorylation is determined for each case, and IC50 value is calculated. |
| In vitro | In obese, insulin-resistant Zucker rats, AZD7545 eliminated postprandial hyperglycemia. AZD7545 increased the percentage of active PDH in the liver and skeletal muscle of Wistar rats. |
| In vivo | AZD7545 inhibits pyruvate dehydrogenase kinase (PDHK) activity by disrupting the interaction between the inner lipoic acid domain of PDHK2 and the dihydrolipoamide acetyltransferase component of the pyruvate dehydrogenase complex (PDC). It increases the activity of pyruvate dehydrogenase (PDH) in primary rat hepatocytes with an EC50 of 105 nM. In the presence of recombinant human PDHK2, AZD7545 also enhances PDH activity, achieving an EC50 of 5.2 nM. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble)
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (6.89 mM), Sonication is recommended.
Ethanol : 88 mg/mL (183.77 mM), Sonication is recommended.
DMSO : 75 mg/mL (156.62 mM), Sonication is recommended.
|
| Keywords | Pyruvate dehydrogenase kinase | PDHK2 | PDHK1 | PDHK | PDH kinase | PDH | Inhibitor | inhibit | AZD-7545 | AZD7545 | AZD 7545 |
| Inhibitors Related | Disulfiram | 1-Methoxy-4-propylbenzene | Mycophenolate Mofetil | Ribavirin | 18β-Glycyrrhetinic acid | Benzyl alcohol | 2-Methylaminoethanol | Methotrexate disodium | D-(-)-3-Phosphoglyceric acid disodium | D-Mannitol | Isomalt | Sodium Oxamate |
| Related Compound Libraries | Glycolysis Compound Library | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | ReFRAME Related Library | Kinase Inhibitor Library | Anti-Cancer Metabolism Compound Library | Inhibitor Library | NO PAINS Compound Library | Mitochondria-Targeted Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
United States
